The Indian Journal of Pediatrics

, Volume 73, Issue 4, pp 313–321

New antiviral agents

Authors

    • Division of Infectious DiseasesChildren's Hospital of Michigan
    • Carman and Ann Adams Department of PediatricsWayne State University, School of Medicine
  • Pimpanada Chearskul
    • Division of Infectious DiseasesChildren's Hospital of Michigan
    • Carman and Ann Adams Department of PediatricsWayne State University, School of Medicine
  • Hossam Al-Tatari
    • Division of Infectious DiseasesChildren's Hospital of Michigan
    • Carman and Ann Adams Department of PediatricsWayne State University, School of Medicine
  • Basim Asmar
    • Division of Infectious DiseasesChildren's Hospital of Michigan
    • Carman and Ann Adams Department of PediatricsWayne State University, School of Medicine
New Drugs Antibiotics

DOI: 10.1007/BF02825826

Cite this article as:
Abdel-Haq, N., Chearskul, P., Al-Tatari, H. et al. Indian J Pediatr (2006) 73: 313. doi:10.1007/BF02825826

Abstract

During the last three decades, a better understanding of viral replication and disease states caused by viral infections have led to the development of newer antiviral agents with enhanced activity and better tolerability. This review focuses on newer systemic and topical antiviral agents that are used in treatment of herpes viruses including herpes simplex type-1 (HSV-1) and type-2 (HSV-2), varicella-zoster virus (VZV) and cytomegalovirus CMV) as well as the human papilloma virus (HPV). Included in this article are the agents famiclovir, penciclovir, valganciclovir, imiquimod, docosanole and brivudin.

Key words

Viral infectingSystemic and topical antiviral agentsHerpes viruses

Copyright information

© Dr. K C Chaudhuri Foundation 2006